Hippocampal subfield volume differences between female-to-male transgender individuals with cross-sex hormone therapy and cisgender women

被引:0
|
作者
Kim, Gwang-Won [1 ]
Lee, Mina [2 ]
Lee, Hyun-Suk [2 ]
Park, Kwangsung [1 ,2 ]
Jeong, Gwang-Woo [3 ]
机构
[1] Chonnam Natl Univ, Adv Inst Aging Sci, Gwangju, South Korea
[2] Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Dept Urol, Gwangju, South Korea
[3] Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Dept Radiol, Gwangju, South Korea
基金
新加坡国家研究基金会;
关键词
brain volume; female-to-male transgender individuals; hippocampal subfields; hormone therapy; testosterone; MALE TRANSSEXUALS; MATTER VOLUME; GRAY-MATTER; HUMAN BRAIN; TESTOSTERONE; ACTIVATION; SUBICULUM; SIZE; ORIENTATION; ESTROGEN;
D O I
10.3389/fnins.2025.1477725
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction The prevalence of female-to-male (FtM) transgender individuals has risen recently, yet the effects of cross-sex hormone therapy on volumetric differences in the hippocampal subfields remain poorly understood. This study aimed to evaluate the differences of gray matter (GM) volume, especially focusing on the hippocampal subfields, in FtM transgender individuals and premenopausal cisgender women. Methods Seventeen FtM transgender individuals who had undergone hysterectomies and were receiving testosterone therapy before participating in this study, along with 20 premenopausal women, underwent a single session of T1-weighted magnetic resonance imaging (MRI). Results FtM transgender group had significantly higher free-testosterone (free-T) levels and lower estradiol levels compared with premenopausal women group (p < 0.001). In voxel-wise analysis, FtM transgender individuals showed significantly larger GM volumes in the caudate nucleus, hypothalamus, and thalamus compared with premenopausal women (p < 0.01, FWE-corrected). More specifically, the right hippocampal subiculum volume was larger in FtM transgender individuals (p < 0.05, Bonferroni-corrected), and these volumes were positively correlated with the free-T levels (r = 0.34, p = 0.04). This study revealed the specific hippocampal subfield volume differences in the testosterone-treated FtM transgender group when compared to cisgender premenopausal women group. Discussion These findings might help elucidate the morphological variation of the specific cerebral regions associated with testosterone therapy in FtM transgender individuals and contribute to our understanding of the effects of gender-affirming hormone treatments as well.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The Impact of Gender-Affirming Cross-Sex Hormone Therapy on Primary Headaches in Transgender and Gender Diverse (TGD) Individuals
    Sim, Danielle
    Hassan, Bashar
    Krishna, Samarth
    Bejo, Sarah
    Martheswaran, Tanisha
    Han, Yunah
    Liang, Fan
    Johnson, Emily
    ANNALS OF NEUROLOGY, 2024, 96 : S214 - S214
  • [22] Self-perception of voice in transgender persons during cross-sex hormone therapy
    Bultynck, Charlotte
    Pas, Charlotte
    Defreyne, Justine
    Cosyns, Marjan
    den Heijer, Martin
    T'Sjoen, Guy
    LARYNGOSCOPE, 2017, 127 (12): : 2796 - 2804
  • [23] A Structural Magnetic Resonance Imaging Study in Transgender Persons on Cross-Sex Hormone Therapy
    Mueller, Sven C.
    Landre, Lionel
    Wierckx, Katrien
    T'Sjoen, Guy
    NEUROENDOCRINOLOGY, 2017, 105 (02) : 123 - 130
  • [24] Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals
    Bunck, Mathijs C.
    Giltay, Erik J.
    Diamant, Michaela
    Gooren, Louis J.
    Teerlink, Tom
    ATHEROSCLEROSIS, 2009, 206 (01) : 245 - 250
  • [25] Perceived Barriers and Facilitators to Integrating HIV Prevention and Treatment with Cross-Sex Hormone Therapy for Transgender Women in Lima, Peru
    Reisner, Sari L.
    Perez-Brumer, Amaya G.
    McLean, Sarah A.
    Lama, Javier R.
    Silva-Santisteban, Alfonso
    Huerta, Leyla
    Sanchez, Jorge
    Clark, Jesse L.
    Mimiaga, Matthew J.
    Mayer, Kenneth H.
    AIDS AND BEHAVIOR, 2017, 21 (12) : 3299 - 3311
  • [26] Perceived Barriers and Facilitators to Integrating HIV Prevention and Treatment with Cross-Sex Hormone Therapy for Transgender Women in Lima, Peru
    Sari L. Reisner
    Amaya G. Perez-Brumer
    Sarah A. McLean
    Javier R. Lama
    Alfonso Silva-Santisteban
    Leyla Huerta
    Jorge Sanchez
    Jesse L. Clark
    Matthew J. Mimiaga
    Kenneth H. Mayer
    AIDS and Behavior, 2017, 21 : 3299 - 3311
  • [27] Cross-Sex Hormone Therapy Is Associated With Loss of Circadian Rhythm in the Male Rat
    Mallette, Jordan H.
    Crudup, Breland F.
    Speyrer, Adrian Oudomrath
    Rawls, Adam Z.
    Cockrell, Kathy
    Willis, Alex T.
    Davenport, Kacey
    Cardozo, Licy L. Yanes
    Shawky, Noha M.
    Alexander, Barbara T.
    HYPERTENSION, 2025, 82 (02) : 241 - 254
  • [28] Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual
    Bergoglio, Marina T.
    Gomez-Balaguer, Marcelino
    Almonacid Folch, Elena
    Hurtado Murillo, Felipe
    Hernandez-Mijares, Antonio
    ENDOCRINOLOGIA Y NUTRICION, 2013, 60 (05): : 264 - 267
  • [29] (Patho)physiology of cross-sex hormone administration to transsexual people: the potential impact of male-female genetic differences
    Gooren, L. J.
    Kreukels, B.
    Lapauw, B.
    Giltay, E. J.
    ANDROLOGIA, 2015, 47 (01) : 5 - 19
  • [30] Cross-sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare
    Bretherton, Ingrid
    Thrower, Emily
    Grossmann, Mathis
    Zajac, Jeffrey D.
    Cheung, Ada S.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (02) : 182 - 188